[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"steroid-resistant-pemphigus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:steroid-resistant-pemphigus":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100569628",false,"NCT06696716","ONO-4059 Study in Patients With Steroid-resistant Pemphigus","ONO-4059-10:Multicenter, Placebo-controlled, Randomized, Double-blind, Phase 3 Study in Patients With Steroid-resistant Pemphigus (BRILLIANT Study)","Inclusion Criteria:\n\n* Patients with a diagnosis of pemphigus\n* Patients with a re-increase in the pemphigus disease area index (PDAI) score before oral corticosteroid tapering to 10mg\u002Fday of prednisolone (PSL) equivalent\n\nExclusion Criteria:\n\n* Patients with an active infection\n* Patients with malignancy\n* Patients with past history of serious allergy or anaphylaxis","ALL","20 Years",{"count":18,"type":19},34,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","ONO-4059-10:Multicenter, placebo-controlled, randomized, double-blind, Phase 3 study in patients with steroid-resistant pemphigus",[25,26],"Pemphigus","Steroid-resistant Pemphigus","RECRUITING","2026-01-05",{"date":30,"type":31},"2026-01-07","ACTUAL",{"date":33,"type":31},"2022-08-15",{"date":35,"type":19},"2029-03-31",{"name":37,"class":38},"Ono Pharmaceutical Co., Ltd.","INDUSTRY",25,""]